Inventiva stock
Price history
−18.70% over the period1 year: from €3.61 (November 20, 2025) to €2.94 (November 20, 2026), −18.70%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €2.94 |
| October 30, 2026 | €3.18 |
| September 30, 2026 | €3.30 |
| August 31, 2026 | €4.05 |
| July 31, 2026 | €3.80 |
| June 30, 2026 | €3.22 |
| May 29, 2026 | €4.28 |
| April 30, 2026 | €4.31 |
| March 31, 2026 | €4.75 |
| February 27, 2026 | €5.49 |
| January 30, 2026 | €5.00 |
| December 31, 2025 | €3.94 |
| November 28, 2025 | €3.66 |
| November 20, 2025 | €3.61 |
At a glance
The company
Clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis and other diseases
Latest results
Quarter to June 30, 2026 · EPS -€0.18 (estimate -€0.47)
Where the price stands
−52.66% from the 52-week high
Analysts · 5 analysts
Average target€9.06+208.55% vs. price
Buy 5 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Inventiva
Compared with similar companies: very high price, very weak momentum, and very low growth.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high91
How much it costs relative to what it produces.
Metric Value Position in group Price/book 13.6 84 Price/sales 330.0 99 Profitabilityvery low20
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 78.3% 58 Operating marginabove 100%: likely one-off items −5,980.9% 2 Net margin 0.0% 31 ROE −989.1% 1 ROA −42.7% 6 Earnings stabilityvery low16
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Margin variabilitycounts in reverse: lower means more earnings stability 662.9% 20 Growthvery low11
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −27.92% 6 Earnings growth (year over year) −84.29% 22 Revenue growth (year over year) −76.70% 4 Financial strengthlow27
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −3.96 21 Current ratio 3.81 57 Debt/equitycounts in reverse: lower means more financial strength 2.35 3 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak9
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −20.87% 8 Relative strength (6 months) −32.16% 9 1-year return −18.70% 12 Distance from 200-day average −26.66% 6 Riskhigh71
How much the price swings.
Metric Value Position in group Beta (1 year) 0.37 17 Volatility (60 days) 77.5% 99 Maximum drawdown (12 months) 55.8% 96
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Inventiva is pricier than similar companies
Inventiva's Price/book: 13.6, +205% against the median of a group of 10 similar companies (4.45).
Compared with 11 similar companies
| Metric | Inventiva | Position in the group | Band |
|---|---|---|---|
| Operating margin | -5,980.9% | Low | |
| ROE | -989.1% | Low | |
| Debt/equity | 2.35 | High | |
| Price/book | 13.6 | High | |
| Net margin | 0.0% | Middle |
Grey band: the middle half of the group; tick: the median; dot: Inventiva. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€1.31M
Latest quarter · Q2 2026
Net income
-€69.47M
Latest quarter · Q2 2026
Quarterly net margin
-5,323.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €810.56M
- EPS
- -€0.53
- Volume
- 408.93K
- Daily trading
- €1.87M
- Dividend yield
- 0.00%
How Inventiva is changing
All resultsRevenue grew 5.1% a year on average over the last 5 years
Operating margin fell from −316.6% to −1,965.5%
Shares outstanding up 451.4% in 5 years
Returns
Inventiva returns
€1,000 invested in Inventiva 5 years ago, on November 22, 2021, would be worth €249 today: −75.13% in total, −24.32% per year. This is the price return only: dividends are excluded.
| Period | Inventiva | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +1.21% | +1.14% | €1,012 |
| 6 months | −33.75% | −2.34% | €663 |
| Year to date | −25.60% | −2.72% | €744 |
| 1 year | −18.70% | −0.67% | €813 |
| 3 years | −20.78% | +9.39% | €792 |
| 5 years | −75.13% | +11.58% | €249 |
Over the last 6 months it has done better than 4% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Inventiva: technical analysis
Inventiva is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.1% below its all-time closing high (€15.56, January 21, 2021).
- Trend
- Downward
- RSI (14 sessions)
- 43
- Between 30 and 70
- vs 200-session average
- −26.66%
Active signals
The last session opened more than 3% below the previous close.
Support and resistance
Price areas where Inventiva has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€3.57+21.64%2 touches, last on August 4, 2026
- Resistance€3.36+14.48%2 touches, last on September 30, 2026
- Resistance€3.11+5.96%2 touches, last on November 2, 2026
- Last price€2.94
- Support€2.73−6.98%2 touches, last on September 25, 2026
Volatility and risk
Over the last year it has moved little with the CAC 40.
- Beta (1 year) vs CAC 40
- 0.37
- Volatility (60 sessions, annualised)
- 77.5%
- Largest fall in the last year
- −55.77%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Inventiva: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for Inventiva has been August: +9.81% on average, positive in 5 years out of 10. The weakest has been April: −6.97% on average, positive in 2 years out of 10. November, the current month, has been positive in 4 years out of 9 (+0.45% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +9.65% | +7.00% | 7 of 9 |
| February | −5.56% | 0.00% | 4 of 9 |
| March | −3.80% | −6.02% | 3 of 10 |
| April | −6.97% | −9.28% | 2 of 10 |
| May | +4.35% | +1.21% | 5 of 10 |
| June | +9.66% | −6.93% | 3 of 10 |
| July | −3.34% | −1.28% | 4 of 10 |
| August | +9.81% | +2.55% | 5 of 10 |
| September | −4.32% | −4.38% | 3 of 10 |
| October | +2.38% | −2.44% | 4 of 10 |
| November | +0.45% | −1.67% | 4 of 9 |
| December | +2.84% | +7.06% | 5 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Inventiva and its competitors
Patients with metabolic dysfunction-associated steatohepatitis, known as MASH, and with mucopolysaccharidoses are among the groups this company develops treatments for, in France and in other countries. Its activity centres on orally administered small molecules aimed at MASH and other diseases, and its research pipeline is at clinical and pre-clinical stages. Lanifibranor, a peroxisome proliferator-activated receptor agonist, is in the NATiV3 Phase 3 trial in adult patients with MASH. Odiparcil targets mucopolysaccharidoses, and a pre-clinical TGF-β program addresses idiopathic pulmonary fibrosis.
- Headquarters
- Daix, France
- Employees
- 87
- Founded
- 2011
- Chief executive
- Andrew Obenshain
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
| GubraGUBRA | $730.02M | -73.1% | — | −22.24% |
| Pharma MarPHM | $1.1B | 21.3% | 14.7 | −41.56% |
Same industry or related industries, similar size. Compare Inventiva with its competitors · Full profile
